Score System for Prediction Risk and Early Diagnosis of HCC in HIV/HCV Patients
NCT ID: NCT02113865
Last Updated: 2015-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2013-10-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatocellular Carcinoma in HIV-infected Patients
NCT02785835
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
NCT01208376
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
NCT05510908
Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients
NCT02628340
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
NCT07146529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective:
The main objective is try to stablish a descriptive panel (first phase of a score system) based in the conjunction or sum of several clinical and laboratory parameters (molecular and genetic factors). The aim is to detect in a fast, early and successful way those patients that presents a high risk to develop an hepatocellular carcinoma (HCC) in the future in a specific population: HIV and HCV coinfected patients. The establishment of this panel will allow clinicians set up a correct treatment decreasing the probability of liver cirrhosis and HCC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Grupo 0
Null or mild fibrosis
No interventions assigned to this group
Grupo 1
Cirrhosis
No interventions assigned to this group
Grupo 2
HCC diagnosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hepatitis C virus chronic infection
* No other liver viral coinfections
Exclusion Criteria
* Immunosuppressor or immunoactive treatment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Mutua Madrileña
OTHER
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beatriz S Sastre, PhD
Role: PRINCIPAL_INVESTIGATOR
Fundación para la Investigación Biomédica del Hospital Ramón y Cajal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Ramón y Cajal
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMM115392013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.